Research programme: Pneumococcal antibodies - Kyowa Hakko Kirin/Valneva

Drug Profile

Research programme: Pneumococcal antibodies - Kyowa Hakko Kirin/Valneva

Alternative Names: Pneumococcus antibodies - Kyowa Hakko Kirin/Valneva; Streptococcus pneumoniae antibodies - Kyowa Hakko Kirin/Valneva

Latest Information Update: 02 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercell
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pneumococcal infections

Most Recent Events

  • 02 Jul 2013 Pneumococcal antibodies are still in preclinical development for Streptococcus pneumoniae, presumably in Japan and Austria
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 18 Dec 2008 A phase I clinical trial in elderly subjects is being planned
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top